Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 5, 2012, Pages 442-448

  Baldasseroni, S ^a   Urso, R ^b   Maggioni, A P ^b   Orso, F ^a   Fabbri, G ^b   Marchionni, N ^a   Tavazzi, L ^c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

^c MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Body mass index; Heart failure; Prognosis; Uric acid

Indexed keywords

URIC ACID;

AGED; AMBULATORY CARE; ARTICLE; BIOLOGICAL MODEL; BLOOD; BODY MASS; BODY WEIGHT; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERURICEMIA; ITALY; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; SURVIVAL;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; BODY MASS INDEX; FEMALE; HEART FAILURE; HUMANS; HYPERURICEMIA; ITALY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MORTALITY; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THINNESS; URIC ACID;

SUBGROUP A;

EID: 84859972126     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.08.007     Document Type: Article

References (29)

1. Nagaya N., Uematsu M., Satoh T., Kyotani S., Sakamaki F., Nakanishi N., et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:487-492.
2. Hayabuchi Y., Matsuoka S., Akita H., Kuroda Y. Hyperuricemia in cyanotic congenital heart disease. Eur J Pediatr 1993, 152:873-876.
3. Hasday J.D., Grum C.M. Nocturnal increase of urinary uric acid: creatinine ratio. A biochemical correlate of sleep-associated hypoxemia. Am Rev Respir Dis 1987, 135:534-538.
4. Feig D.I., Kang D.-H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-1821.
5. De Jong J.W., Schoemaker R.G., De Jonge R., Bernocchi P., Keijzer E., Harrison R., et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol 2000, 32:2083-2089.
6. Hare J.M., Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 2003, 107:1951-1953.
7. Roch-Ramel F., Guisan B., Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997, 280:839-845.
8. Leyva F., Chua T.P., Godsland I.F., Coats A.J., Anker S.D. Loss the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Heart 1999, 82:348-351.
9. Leyva F., Anker S.D., Godsland I.F., Teixeira M., Hellewell P.G., Kox W.J., et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998, 19:1814-1822.
10. Anker S.D., Levya F., Poole-Wilson P.A., Kox W.J., Stevenson J.C., Coats A.J. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 1997, 78:39-43.
11. Kalemkerian G.P., Darwish B., Varterasian M.L. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997, 103:363-367.
12. Anker S.D., Negassa A., Coats A.J., Afzal R., Poole-Wilson P.A., Cohn J.N., et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003, 361:1077-1083.
13. Alcaino H., Greig D., Chiong M., Verdejo H., Miranda R., Concepcion R., et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008, 10:646-651.
14. Doehner W., Anker S.D. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?. Heart 2005, 91:707-709.
15. Hare J.M., Mangal B., Brown J., Fisher C., Freudenberger R., Colucci W.S., et al. OPT-CHF Investigators. Impact of oxipurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51:2301-2309.
16. Baldasseroni S., Opasich C., Gorini M., Lucci D., Marchionni N., Marini M., et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure. Am Heart J 2002, 143:398-405.
17. The Task Force on Heart Failure of the European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001, 22:1527-1560.
18. SAS Institute Inc SAS Technical report, SAS/STAT software 1992, release 6.07, SAS Institute, Cary NC.
19. R Development Core Team R: A language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna, Austria. http://www.r-project.org.
20. Harrell F.E., Lee K.L., Pollock B.G. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst 1988, 80:1198-1202.
21. Heagerty P.J., Lumley T., Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56:337-344.
22. Mann D.L. Mechanisms and models in heart failure. A combinatorial approach. Ciculation 1999, 100:999-1008.
23. Strasak A.M., Kelleher C.C., Brant L.J., Rapp K., Ruttmann E., Concin H., et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008, 125(2):232-239.
24. Doenher W., Rauchhaus M., Florea V.G., Sharma R., Bolger A.P., Davos C.H., et al. Uric acid in cachectic and non cachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 2001, 141(5):792-799.
25. Anker S.D., Doenher W., Rauchaus M., Sharma R., Francis D., Knosalla C., et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional and haemodynamic staging. Circulation 2003, 107:1991-1997.
26. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized double-blind placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
27. Cappola T.P., Kass D.A., Nelson G.S., Berger R.D., Rosas G.O., Kobeissi Z.A., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001, 104:2407-2411.
28. Farquharson C.A., Butler R., Hill A., Belch J.J., Struthers A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
29. Ogino K., Kato M., Furuse Y., Kinugasa Y., Ishida K., Osaki S., et al. Uric acid lowering treatment with benzbromarone in patients with heart failure: a double blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010, 3(1):73-81.